Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 8—August 2004


Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management

Deborah S. Yokoe*Comments to Author , Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA

Main Article

Table 2

Reasons for meeting pharmacy screening criteria among persons without active tuberculosis (TB)

Reasons why non-TB cases met screening criteria Plan A (%) Plan B (%) Plan C (%) Total (%)
Suspected active TB, full course of therapy 7 (13) 0 8 (9) 15 (10)
Suspected active TB, empiric therapy discontinued 12 (22) 0 35 (38) 47 (31)
Treatment of latent TB infection 8 (14) 3 (43) 10 (11) 21 (14)
Other mycobacterial infections 26 (47) 4 (57) 33 (36) 63 (41)
Other or unknown 2 (4) 0 5 (5) 7 (4)
Total 55 7 91 153

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO